Search this site

Boeing has beaten Northrop Grumman for a $20 billion Navy fighter contract. The award expands its defence pipeline, but investors will be watching whether it can deliver two major jet programmes at once. Boeing has won a $20 billion contract to develop the US Navy’s next-generation fighter jet, beating rival Northrop Grumman. The award covers development and test aircraft. If the programme moves into full production, its value could grow substantially over the coming decades. Boeing shares rose in premarket trading on Wednesday, while Northrop Grumman shares fell. A major win with a demanding timetable The contract gives Boeing a second high-profile fighter programme after it won the Air Force’s F-47 project last year. It also brings fresh work to the company’s defence operations as production of its older Navy fighters winds down. For investors, the win strengthens Boeing’s long-term defence pipeline. The question now is execution: Boeing must assemble the engineers, suppliers and production capacity to deliver two advanced aircraft programmes. The first production Navy jets are expected in the 2030s, so the contract’s full financial benefit will take years to emerge.

AstraZeneca has asked the FDA to approve ORPATHYS with TAGRISSO for certain patients with advanced lung cancer. Trial results support the application, while the US regulator’s decision remains the next key step. AstraZeneca and HUTCHMED have taken another step toward bringing a lung cancer treatment combination to the US market. AstraZeneca has applied to the Food and Drug Administration for approval of ORPATHYS alongside TAGRISSO for patients with advanced lung cancer whose disease progressed after earlier EGFR-targeted treatment. According to HUTCHMED, the combination extended the time patients lived without their cancer worsening and improved overall survival compared with chemotherapy. ORPATHYS is jointly developed by the two companies and commercialised by AstraZeneca. The application matters to investors because it could expand the reach of an existing AstraZeneca cancer medicine while creating a US opportunity for its partner’s drug. ORPATHYS has already received approval in China based on a separate late-stage study. The US decision is still ahead. Investors will now watch the FDA review and the eventual terms of any approval before judging the size of the commercial opportunity.

Shell and its partners have approved an expansion that would double LNG Canada’s annual capacity. The project promises more gas for Shell in the early 2030s, with costs and future prices shaping its return. Shell and its partners have approved a major expansion of LNG Canada, committing to more export capacity years before it is expected to come online. The second phase will add two processing units at the facility in British Columbia. That would lift annual capacity from 14 million to roughly 28 million tonnes of liquefied natural gas. Commercial operations are targeted for the early 2030s. Shell owns 40% of the joint venture and expects to receive nearly six million additional tonnes of LNG a year from the expansion. The decision commits the partners to a multibillion-dollar project and signals confidence in demand for Canadian gas exports. For Shell investors, the project offers a route to greater LNG supply over the long term. Its returns will depend on construction costs, delivery and the prices Shell can secure when the additional gas reaches customers. The approval moves LNG Canada’s expansion from a proposal to a major investment commitment. The financial payoff, however, is still years away.

Middle East oil exports are recovering, led by Saudi Arabia, but remain about 6 million barrels a day below February levels. October shipments will show whether the improvement can last. Oil shipments from key Middle East producers have rebounded this month, offering a clearer picture of how much supply has returned to the market. Exports are on track to reach 12.8 million barrels a day in September, according to preliminary data from Kpler. That is the highest level since the conflict with Iran began in February. Saudi Arabia has been a major driver of the increase, with its shipments expected to rise to about 5.4 million barrels a day from 2.45 million in August. The recovery could ease some pressure on buyers if the shipments continue. For oil producers, refiners and transport companies, the volume of oil actually leaving the region matters as much as daily moves in crude prices. Supply has yet to return to its earlier level. Regional exports remain about 6 million barrels a day below February’s 18.8 million, according to Kpler. The September figures are also preliminary. Investors will be watching whether the rise in shipments holds through October. A sustained recovery would improve the supply outlook; renewed disruption would leave the market exposed to a substantial gap.

AAR is buying control of aircraft maintenance firm MRO Holdings for $1.8 billion. The deal adds capacity as airlines keep older jets flying, but investors will weigh that growth against its financing costs. Airlines are keeping aircraft in service for longer, and AAR wants a larger share of the work required to maintain them. The US aviation services company has agreed to buy a 65% stake in MRO Holdings for about $1.8 billion. Together, the businesses would have capacity to service nearly 3,000 aircraft a year in their maintenance hangars. The deal would expand AAR’s operations across the US and Latin America. It also comes as delays in new aircraft deliveries and supply chain constraints increase demand for work on existing fleets. AAR plans to fund the purchase with new debt, roughly $780 million in shares issued to MRO Holdings shareholders, and proceeds from a separate equity investment. It will have the option to buy the remaining 35% within six years of closing. For investors, the opportunity is clear: more maintenance capacity in a market where airlines need it. The question is whether that growth will outweigh the cost of financing the deal and issuing new shares. The transaction is expected to close by February 2027, subject to regulatory approval and other conditions.

A £43 million Cornwall lithium facility has received an offer of nearly £10 million in UK government support. Production is planned for 2029, leaving funding approval and commercial execution as the key tests. Britain is putting public funding behind another domestic lithium project, giving its battery supply ambitions a more concrete test. Geothermal Engineering Limited plans to invest around £43 million in a Cornwall facility that will extract lithium from underground geothermal brine. The project has received an offer in principle of nearly £10 million through a UK government programme supporting the automotive supply chain. Commercial production is expected to begin in 2029. At that stage, the facility is projected to produce roughly 1,500 tonnes of technical-grade lithium carbonate a year. For investors, the significant point is the move from discussing domestic resources to financing a production facility. Lithium is an essential battery material, and a local supply could become valuable to manufacturers seeking more reliable sources. The project is still at an early stage. The government’s funding offer requires due diligence and final approval, while the planned output remains several years away. Construction, operating costs and eventual demand will determine whether the facility becomes commercially competitive. The next milestones are finalising the funding and showing that the extraction process can work at the planned scale.

The FDA has approved Roche’s Gazyva for certain patients with a rare kidney condition. The new use expands the drug’s market, while adoption and sales will determine its financial impact. Roche has secured another approved use for Gazyva, expanding the drug’s reach into a rare kidney condition. The US Food and Drug Administration approved Gazyva to reduce the risk of relapse in certain patients aged two and older with childhood-onset idiopathic nephrotic syndrome. The approval applies to patients who are in remission but have frequent relapses or depend on steroids. Gazyva is already used for certain cancers and for adults with active lupus nephritis. This new indication gives Roche another group of patients it can treat with an established medicine. In an 85-patient late-stage study, Gazyva performed significantly better than a commonly used treatment on the trial’s main measure of remaining in remission. That result supported the FDA’s decision. The commercial opportunity needs perspective. The condition is rare, so this approval alone is unlikely to reshape Roche’s finances. Its value lies in widening Gazyva’s approved uses and strengthening the case for the drug in kidney disease. Investors will now watch how quickly doctors adopt the treatment and whether Roche can turn the new approval into meaningful additional sales.

The US and China have agreed to tariff reductions covering $60 billion in trade. Exporters and retailers may benefit, but the value of the deal will depend on its final terms and implementation. The US and China have agreed to reduce tariffs on $60 billion worth of goods, giving some exporters and retailers a clearer path through a trade relationship that remains uncertain. Each country has identified $30 billion in goods for more favourable treatment. China’s list includes US corn, wheat, meat and dairy products, while the US list covers Chinese household goods such as small appliances, bedding and toys. Soybeans, a major US agricultural export, are absent from the announced Chinese list. The two countries have also extended their trade truce through January 10. For businesses deciding where to source products or invest, that extra time offers some stability. The investor impact will depend on which tariff changes take effect and whether companies can turn lower costs or better market access into stronger sales and margins. The agreement is broad enough to matter across agriculture and consumer goods, but its benefits will vary considerably by company. The next test is implementation. Investors will be watching the final tariff terms and whether the two countries extend the truce again before it expires.

Micron reports earnings on Wednesday after forecasting roughly $50 billion in quarterly revenue. Investors will focus on AI memory demand, margins and whether the next outlook supports the sector’s high expectations. Micron’s results on Wednesday will give investors a fresh measure of how much the AI buildout is worth to memory chipmakers. The company’s last quarter set a high bar. Revenue reached $41.46 billion, and Micron forecast about $50 billion in revenue for its fiscal fourth quarter, with a gross margin of approximately 86%. Its cloud memory and data centre businesses both grew sharply as demand for AI infrastructure increased. Those figures make this week’s report about more than whether Micron meets its own forecast. Investors will want to know whether customers are still buying memory at a pace that supports strong pricing and whether Micron can maintain its margins as it invests in more production. High-bandwidth memory is a particular focus. It is used alongside advanced AI processors, making Micron’s comments on shipments and customer demand relevant well beyond its own shares. Expectations are already substantial. A strong quarter may therefore need an equally strong outlook to reassure investors that the recent growth can continue. The company’s guidance for the following quarter will be the clearest test.

Genentech's potential $1.5 billion Earendil Labs partnership gives AI-designed cancer drugs another major test inside the pharmaceutical industry. Genentech is putting more money behind the idea that artificial intelligence can help build better medicines. The Roche-owned biotechnology company has signed a collaboration with Earendil Labs to discover and develop bispecific antibodies for cancer. Earendil will receive $55 million upfront, while development, regulatory and commercial milestones could eventually push the agreement above $1.5 billion. The company combines AI-driven protein design with large-scale experimental testing to develop biologic medicines. Under the agreement, Earendil will lead discovery and early development, while Genentech would take responsibility for later clinical development and commercialization. Big Pharma tests AI The structure of the agreement is important. The $1.5 billion headline figure is not guaranteed. Most of the money depends on Earendil's programs successfully reaching future milestones, limiting Genentech's upfront risk. That reflects the wider position of AI in drug discovery. Technology companies have argued that AI can identify promising medicines faster and more efficiently, potentially reducing one of the pharmaceutical industry's biggest costs. But discovering a candidate is only the beginning. AI-designed medicines must still survive clinical trials and regulatory review like any other drug. Genentech's agreement shows that major pharmaceutical companies are willing to put serious capital behind the technology. The bigger test will be whether these partnerships eventually produce approved medicines rather than promising algorithms.

Norway is pushing ahead with the Fen Complex, a 15.9-million-tonne rare-earth resource that could strengthen Europe's critical-minerals supply chain. Europe wants to reduce its dependence on imported critical minerals. Norway may have one of the resources needed to make that possible. The Norwegian government is targeting 2028 for a development plan covering the Fen Complex, Europe's largest known rare-earth deposit. Fen is estimated to contain approximately 15.9 million tonnes of rare-earth oxides, including materials used to manufacture powerful permanent magnets for electric vehicles, wind turbines and advanced technology. That gives the project strategic importance well beyond Norway. From resource to mine China dominates much of the global rare-earth supply chain, particularly processing. Western governments have therefore been encouraging investment in alternative sources. But discovering minerals and producing them competitively are very different things. Fen still faces environmental, permitting and processing challenges. Those hurdles have slowed critical-mineral projects elsewhere, even as governments push for greater supply-chain independence. For investors, the project's enormous resource is therefore only part of the equation. Development costs, approvals, processing capacity and eventual production economics will determine whether Fen becomes an important European supplier or remains a promising deposit in the ground. A 2028 development plan would be a significant step. Europe has identified the resource. Turning it into a commercially competitive mine is the harder part.

ADARx has raised $446 million in an upsized Nasdaq IPO, providing another test of returning investor appetite for biotechnology companies. ADARx Pharmaceuticals has raised $446.3 million in an upsized IPO, providing another test of returning investor appetite for biotechnology stocks. The drug developer sold 26.25 million shares at $17 each, the top of its marketed range, after increasing the size of the offering. Shares are expected to begin trading on Nasdaq under the ticker ADRX. The company develops treatments using small interfering RNA, or siRNA, technology, which is designed to silence genes involved in disease. Its most advanced candidate, onvuzosiran, is being developed for hereditary angioedema and has reached late-stage clinical testing. AbbVie adds its backing ADARx also has support from one of the world's largest pharmaceutical companies. AbbVie is making a separate investment alongside the IPO and is expected to hold approximately 4.9% of ADARx once the transactions close. Combined gross proceeds could reach roughly $535 million. The companies already work together on potential siRNA treatments across neuroscience, immunology and oncology. For investors, ADARx is also part of a wider story. Biotech companies depend heavily on capital markets because developing drugs can require years of spending before meaningful revenue arrives. A stronger IPO market gives promising developers another route to fund expensive clinical trials. Pricing at the top of its range and increasing the offering suggests ADARx found substantial demand. The next question is whether that enthusiasm lasts beyond the IPO — and whether its clinical pipeline can ultimately justify it.